Skip to Main Content

Bluebird Bio (BLUE) is surprising investors Friday with some unexpectedly good news out of Europe.

A marketing application covering the Cambridge, Mass., biotech’s gene therapy for beta thalassemia was accepted for review by European regulators, Bluebird announced.


Bluebird was sneaky — in a good way. Based on the company’s prior guidance, investors were expecting Bluebird to announce a European regulatory filing before the end of the year. Instead, Bluebird went ahead and submitted its gene therapy, called LentiGlobin, without telling anyone. Friday’s public announcement means the European review process for LentiGlobin is ahead of schedule.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.